Rapid Dose Therapeutics (XCNQ:DOSE) Cash-to-Debt : 0.06 (As of Nov. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Rapid Dose Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Rapid Dose Therapeutics's cash to debt ratio for the quarter that ended in Nov. 2023 was 0.06.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Rapid Dose Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Nov. 2023.

The historical rank and industry rank for Rapid Dose Therapeutics's Cash-to-Debt or its related term are showing as below:

XCNQ:DOSE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.39 Max: No Debt
Current: 0.06

During the past 13 years, Rapid Dose Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.39.

XCNQ:DOSE's Cash-to-Debt is ranked worse than
95.97% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs XCNQ:DOSE: 0.06

Rapid Dose Therapeutics Cash-to-Debt Historical Data

The historical data trend for Rapid Dose Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Rapid Dose Therapeutics Cash-to-Debt Chart

Rapid Dose Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Feb19

Feb20

Feb21

Feb22

Feb23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.03

0.02

Rapid Dose Therapeutics Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Cash-to-Debt	Get a 7-Day Free Trial															0.02	0.02	0.02	0.08	0.06

Competitive Comparison of Rapid Dose Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Rapid Dose Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Cash-to-Debt falls into.

Rapid Dose Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Rapid Dose Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Feb. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.028	/	(1.395	+	0.216)
	=	0.02

Rapid Dose Therapeutics's Cash to Debt Ratio for the quarter that ended in Nov. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.166	/	(0.766	+	1.99)
	=	0.06

Rapid Dose Therapeutics (XCNQ:DOSE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Rapid Dose Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics (XCNQ:DOSE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (XCNQ:DOSE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RDTCF:USA

Address

1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4

Website

http://www.rapid-dose.com

Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

Rapid Dose Therapeutics (XCNQ:DOSE) Headlines

No Headlines